Immune checkpoint modulators led the growth in immuno-oncology trials for 2008–2017

24th April 2018 (Last Updated April 24th, 2018 14:24)

GlobalData has reviewed the growth of global clinical trials in the immuno-oncology (IO) space that were initiated between 2008 and 2017.

GlobalData has reviewed the growth of global clinical trials in the immuno-oncology (IO) space that were initiated between 2008 and 2017. IO trials were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center using an ‘immuno-oncology’ filter based on drugs tagging.

Immuno-oncology therapies are separated into four broad segments:

  • Adoptive cellular therapy, which includes chimeric antigen receptor T-cell immunotherapy (CAR-T), cytotoxic T lymphocyte immunotherapy (CTL), natural killer cell immunotherapy (NKT), regulatory T cells (Treg), and tumor-infiltrating lymphocyte immunotherapy (TIL).
  • Immune checkpoint modulators.
  • Immune system modulators, which include various cancer vaccines.
  • Immunomodulatory enzyme inhibitors.

The highest growth was attributed to immune checkpoint modulators, where the number of trials increased at a much higher rate than the other IO segments, concurrent with the surge in investigations into PD-1 targets (see Figure 1).

Figure 1: global IO clinical trials, N, by segment

Source: GlobalData. © GlobalData

Related Reports

GlobalData (2017). PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities, August 2017, Report Code: GDHC009PFR.

For more insight and data, visit the GlobalData Report Store - Drug Development Technology is part of GlobalData Plc.